Emerald Mutual Fund Advisers Trust Acquires New Stake in Palvella Therapeutics, Inc. $PVLA

Emerald Mutual Fund Advisers Trust bought a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 105,820 shares of the company’s stock, valued at approximately $13,190,000.

Other institutional investors have also added to or reduced their stakes in the company. Group One Trading LLC raised its holdings in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after acquiring an additional 200 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics during the third quarter valued at about $36,000. China Universal Asset Management Co. Ltd. bought a new stake in Palvella Therapeutics during the fourth quarter worth about $167,000. Keybank National Association OH bought a new stake in Palvella Therapeutics during the first quarter worth about $228,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $238,000. 40.11% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Palvella Therapeutics Trading Up 0.9%

PVLA opened at $146.03 on Tuesday. The company has a market cap of $2.09 billion, a P/E ratio of -35.02 and a beta of -0.20. The business’s 50-day moving average price is $123.01 and its 200-day moving average price is $114.06. Palvella Therapeutics, Inc. has a 12 month low of $25.80 and a 12 month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Equities research analysts forecast that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Chardan Capital reiterated a “buy” rating and set a $240.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Wall Street Zen downgraded Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. HC Wainwright upped their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Stephens reiterated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.